Overall impact
A (82)

Commentary

Neurogene is a leader for overall positive impact. With an 'A' rating of 81.5 for overall impact (95th percentile compared to all companies), Neurogene ranks 37th out of 645 industry peers, behind Cell Source, Fitlife Brands, Regeneron Pharmaceuticals and 33 others, and ahead of Curium Pharma, Allena Pharmaceuticals, Pluristem Therapeutics and 605 others. On top material causes for Neurogene's industry (Biotechnology), Neurogene performs well in Accountable Institutions (95.2 score), Child and Maternal Health (95.4), Child and Maternal Health (95.4) and 16 other causes where it received an 'A' score and performs poorly in Decent, Safe Work Opportunities (38.2 score) and Decent, Safe Work Opportunities (38.2).
Impact
Cause NGNE
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2018
Employees
91
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
New York, United States
Share classes
NGNE
Description
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
Material causes
Ethos considers the following causes material for Neurogene, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.